Meeting
2013 Gastrointestinal Cancers Symposium
Validation of the survival benefit from metformin use in patients with type 2 diabetes and colorectal cancer.
Authors
Ibrahim Sahin
The University of Texas MD Anderson Cancer Center
Ibrahim Sahin , Hesham Hassabo , Yehua Shen , Bryan Kee , Manal Hassan , Chris Garrett
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon and Rectum
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 31, 2013 (suppl 4; abstr462)
DOI
10.1200/jco.2013.31.4_suppl.462
Abstract #
462
Poster Bd #
C18
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Metformin (M), diabetes (DM), and colorectal cancer (CRC) survival among U.S. veterans.
First Author: Jessica K Paulus
Poster
2019 Gastrointestinal Cancers Symposium
High-serum blood sugar level significantly enhances oxaliplatin resistance in stage III colorectal cancer patients.
First Author: Jaw-Yuan Wang
Poster
2018 ASCO Annual Meeting
Effect of comorbidities on outcomes in colorectal cancer (CRC) survivors.
First Author: Colleen A Cuthbert
Poster
2015 ASCO Annual Meeting
Relationship between metformin use and recurrence and survival in patients (pts) with resected stage III colon cancer (CC) receiving adjuvant chemotherapy: Results from NCCTG N0147 (Alliance).
First Author: Preet Paul Singh